Eteplirsen Approval Could Add $500M/Yr. to Sarepta Therapeutics (SRPT) Top Line - Barron's

Sarepta Therapeutics (Nasdaq: SRPT) is up today following news that it plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) by the end of 2014 for the approval of eteplirsen for the treatment of Duchenne muscular dystrophy (DMD).

Barron's was also positive on the stock over the weekend, saying shares of Sarepta could shoot higher on early approval of eteplirsen. Currently, there are no cures for DMD, which affects about 15,000 boys in the U.S. alone.

Should the FDA decide to grant accelerated approval pending approval of phase II data.

While Sarepta's market cap is at $1.3 billion or so on Monday, Barron's noted that eteplirsen could add about $500 million of to revenue annually.

Though upside for Sarepta could be huge, the company has no other drugs on the market right now and any failure to win U.S. FDA approval would result in the stock price collapsing.

The Barron's piece is here.

Shares of Sarepta are up over 40 percent following today's news and Barron's sees shares doubling from a close at $24.20 last week, meaning minimal upside moving forward even with approval.

You May Also Be Interested In

• Sarepta Therapeutics to Announce First Quarter 2024 Financial Results
• Legend Biotech (LEGN) Reports CARVYKTI Approved in EU
• Adicet Bio (ACET) Highlights Preclinical Data Supporting IND Readiness for ADI-270 in an Oral Presentation